MedTrace Logo

Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects

NCT06621017 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-09-05

No results posted yet for this study

Summary

The primary objective of this study is to assess the efficacy of ROSE-010 on food intake in female subjects with overweight and obesity.

The secondary objectives of this study are the following:

* To assess the efficacy of ROSE-010 on hunger;
* To assess the efficacy of ROSE-010 on satiety;
* To assess the efficacy of ROSE-010 on prospective consumption;
* To assess the efficacy of ROSE-010 on desire to eat;
* To assess the efficacy of ROSE-010 on palatability;
* To characterize the pharmacokinetics (PK) of ROSE-010 following subcutaneous (SC) administration on Day 1 and Day 7; and
* To evaluate safety and tolerability of SC administrations of ROSE-010 to overweight and obese subjects.

Conditions

  • Obesity; Overweight

Interventions

DRUG

ROSE-010 99 mcg

Sub-cutaneous injection of ROSE-010 solution

DRUG

Placebo

Sub-cutaneous injection of saline solution

DRUG

ROSE-010 150 mcg

Sub-cutaneous injection of ROSE-010 solution

Sponsors & Collaborators

  • Rose Pharma Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-26
Primary Completion
2025-02-27
Completion
2025-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06621017 on ClinicalTrials.gov